136 related articles for article (PubMed ID: 38324192)
21. Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.
Levy A; Faivre-Finn C; Hasan B; De Maio E; Berghoff AS; Girard N; Greillier L; Lantuéjoul S; O'Brien M; Reck M; Dingemans AC; Novello S; Berghmans T; Besse B; Hendriks L;
Eur J Cancer; 2018 Apr; 93():37-46. PubMed ID: 29477100
[TBL] [Abstract][Full Text] [Related]
22. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.
Li H; Zhang X; Cao J; Su P; Lian J; Song X; Yang W; Han S; Xi Y; Wang Y
Tumour Biol; 2015 Dec; 36(12):9251-8. PubMed ID: 26091796
[TBL] [Abstract][Full Text] [Related]
23. Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC.
Ju JS; Huang AC; Tung PH; Huang CH; Chiu TH; Wang CC; Ko HW; Chung FT; Hsu PC; Fang YF; Guo YK; Kuo CS; Yang CT
Sci Rep; 2023 Nov; 13(1):20323. PubMed ID: 37989860
[TBL] [Abstract][Full Text] [Related]
24. Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis.
Nigen B; Goronflot T; Herbreteau G; Mathiot L; Sagan C; Raimbourg J; Bennouna J; Thillays F; Pons-Tostivint E
Lung Cancer; 2023 Oct; 184():107321. PubMed ID: 37586178
[TBL] [Abstract][Full Text] [Related]
25. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study.
Choi JH; Choi YW; Lee HW; Kang SY; Jeong GS; Ahn MS; Oh YT; Noh OK; Kim SH; Roh TH; Sheen SS
Korean J Intern Med; 2022 Mar; 37(2):434-443. PubMed ID: 35167736
[TBL] [Abstract][Full Text] [Related]
27. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance.
Chen LJ; Li XY; Zhao YQ; Liu WJ; Wu HJ; Liu J; Mu XQ; Wu HB
Pathol Res Pract; 2017 Aug; 213(8):882-888. PubMed ID: 28688608
[TBL] [Abstract][Full Text] [Related]
28. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
[TBL] [Abstract][Full Text] [Related]
29. A study of non small cell lung cancer (NSCLC) patients with brain metastasis: A single centre experience.
Hatton N; Samuel R; Riaz M; Johnson C; Cheeseman SL; Snee M
Cancer Treat Res Commun; 2023; 34():100673. PubMed ID: 36603538
[TBL] [Abstract][Full Text] [Related]
30. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated
Non-small Cell Lung Cancer and Brain Metastases].
Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.
Sun A; Hu C; Wong SJ; Gore E; Videtic G; Dutta S; Suntharalingam M; Chen Y; Gaspar LE; Choy H
JAMA Oncol; 2019 Jun; 5(6):847-855. PubMed ID: 30869743
[TBL] [Abstract][Full Text] [Related]
32. Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
Shah PP; Franke JL; Medikonda R; Jackson CM; Srivastava S; Choi J; Forde PM; Brahmer JR; Ettinger DS; Feliciano JL; Levy BP; Marrone KA; Naidoo J; Redmond KJ; Kleinberg LR; Lim M
J Neurosurg; 2022 Jan; 136(1):56-66. PubMed ID: 34087798
[TBL] [Abstract][Full Text] [Related]
33. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
Tan WL; Ng QS; Lim C; Tan EH; Toh CK; Ang MK; Kanesvaran R; Jain A; Tan DSW; Lim DW
BMC Cancer; 2018 Dec; 18(1):1198. PubMed ID: 30509246
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
[TBL] [Abstract][Full Text] [Related]
35. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
[TBL] [Abstract][Full Text] [Related]
36. Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer.
Su PL; Wu YL; Chang WY; Ho CL; Tseng YL; Lai WW; Su WC; Lin CC; Yang SC
Ther Adv Med Oncol; 2018; 10():1758835918797589. PubMed ID: 30263066
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
[TBL] [Abstract][Full Text] [Related]
38. Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases.
Zerdes I; Kamali C; Koulouris A; Elsayed M; Schnorbach J; Christopoulos P; Tsakonas G
ESMO Open; 2023 Dec; 8(6):102069. PubMed ID: 37988952
[TBL] [Abstract][Full Text] [Related]
39. Validation of the initial brain metastasis velocity in non-small cell lung cancer at a single cancer center.
Kimura K; Deguchi S; Mitsuya K; Mamesaya N; Kobayashi H; Ko R; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Takahashi T; Hayashi N
J Neurooncol; 2023 Apr; 162(2):435-441. PubMed ID: 36977845
[TBL] [Abstract][Full Text] [Related]
40. Outcome and prognostic factors in single brain metastases from small-cell lung cancer.
Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hörner-Rieber J; König L; Kappes J; Thomas M; Unterberg A; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
Strahlenther Onkol; 2018 Feb; 194(2):98-106. PubMed ID: 29085978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
